import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "adipokine-peptides-visfatin-resistin-omentin-vaspin-metabolic-research",
  title: "Adipokine Peptides: Visfatin, Resistin, Omentin, and Vaspin in Metabolic Research",
  description:
    "Visfatin, resistin, omentin, and vaspin are bioactive peptides secreted by adipose tissue with documented roles in insulin sensitivity, inflammation, and cardiovascular risk. A research-focused overview of their biology and study applications.",
  category: "Research Fundamentals",
  readMinutes: 13,
  publishedAt: "2026-06-17",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "Adipose tissue is now recognized as an active endocrine organ that secretes a broad spectrum of signaling molecules collectively called adipokines. While leptin and adiponectin have received the most attention, a second generation of adipokines — including visfatin (NAMPT/PBEF), resistin, omentin, and vaspin — has accumulated substantial research interest for their roles in metabolic syndrome, type 2 diabetes, and cardiovascular disease. This article provides a research-oriented overview of each compound, covering their origins, mechanisms, and current investigational context.",
    },
    {
      type: "heading",
      text: "Visfatin (NAMPT/PBEF1)",
    },
    {
      type: "subheading",
      text: "Biology and Expression",
    },
    {
      type: "paragraph",
      text: "Visfatin was originally described in 2005 (Fukuhara et al., Science) as a visceral fat-enriched adipokine with insulin-mimetic properties. It is identical to nicotinamide phosphoribosyltransferase (NAMPT) — the rate-limiting enzyme in the NAD+ biosynthesis salvage pathway — and to pre-B cell colony-enhancing factor (PBEF). This triple identity caused significant initial controversy and eventual retraction of some early claims about its insulin receptor agonism. The current consensus recognizes extracellular NAMPT (eNAMPT) as the circulating form with paracrine and endocrine functions distinct from its enzymatic intracellular role.",
    },
    {
      type: "list",
      items: [
        "Gene: NAMPT (chromosome 7q22.3)",
        "Protein: 491 amino acids; homodimeric in active form",
        "Primarily expressed: visceral adipose tissue, liver, muscle, immune cells",
        "Circulating form: eNAMPT (extracellular NAMPT)",
        "Enzymatic role: converts nicotinamide to NMN in NAD+ salvage pathway",
      ],
    },
    {
      type: "subheading",
      text: "Research Associations",
    },
    {
      type: "paragraph",
      text: "Plasma visfatin/eNAMPT levels have been positively correlated with visceral obesity, insulin resistance, type 2 diabetes, and cardiovascular disease risk in numerous observational studies. In preclinical models, visfatin has been shown to promote inflammatory cytokine production (IL-6, TNF-α, IL-1β) via NF-κB and MAPK pathways, suggesting it may mediate the link between visceral adiposity and low-grade chronic inflammation.",
    },
    {
      type: "paragraph",
      text: "In cancer research, visfatin/NAMPT has emerged as a target of interest: NAMPT inhibitors (e.g., FK866) have been investigated as potential anti-tumor agents, exploiting cancer cells' dependence on the NAD+ salvage pathway. This dual role — as a metabolic regulator in adipose tissue and a pharmacological target in oncology — makes visfatin a conceptually rich compound for investigators in both fields.",
    },
    {
      type: "heading",
      text: "Resistin",
    },
    {
      type: "subheading",
      text: "Biology and Species Divergence",
    },
    {
      type: "paragraph",
      text: "Resistin was identified in 2001 (Steppan et al., Nature) as a adipocyte-secreted factor that impaired insulin action in mice. The name derives from its proposed role in 'resistance to insulin.' Importantly, resistin biology differs substantially between rodents and humans — a critical distinction for translational research. In rodents, resistin is produced primarily by adipocytes; in humans, it is expressed predominantly by monocytes, macrophages, and neutrophils, with minimal adipocyte contribution. Human resistin is therefore more accurately characterized as an inflammatory molecule than a classic adipokine.",
    },
    {
      type: "table",
      headers: ["Feature", "Rodent Resistin", "Human Resistin"],
      rows: [
        ["Primary source", "White adipocytes", "Monocytes/macrophages"],
        ["Circulating form", "Trimer", "Hexamer (disulfide-bonded)"],
        ["Insulin resistance link", "Strong (direct)", "Indirect (via inflammation)"],
        ["Key receptor", "CAP1 (adenylyl cyclase-associated protein)", "TLR4 (proposed)"],
        ["Inflammatory role", "Modest", "Significant (IL-6, TNF-α induction)"],
      ],
    },
    {
      type: "subheading",
      text: "Research Applications",
    },
    {
      type: "paragraph",
      text: "In human clinical research, elevated plasma resistin levels have been associated with cardiovascular disease, heart failure, rheumatoid arthritis, non-alcoholic fatty liver disease (NAFLD), and inflammatory bowel disease. Given its macrophage origin in humans, resistin appears to function more as a mediator of innate immune activation and chronic inflammation than as a direct insulin antagonist. Investigators studying cardiometabolic disease, autoimmune conditions, or gut inflammation may find resistin a useful biomarker endpoint in mechanistic studies.",
    },
    {
      type: "heading",
      text: "Omentin (Intelectin-1)",
    },
    {
      type: "subheading",
      text: "Biology and Expression",
    },
    {
      type: "paragraph",
      text: "Omentin (also designated intelectin-1 or ITLN1) is a 34 kDa adipokine predominantly expressed in visceral adipose stromal vascular cells — distinguishing it from most adipokines expressed in mature adipocytes. It exists as a homotrimeric protein in circulation and has been characterized as an insulin-sensitizing adipokine with anti-inflammatory properties, making it conceptually complementary to adiponectin.",
    },
    {
      type: "list",
      items: [
        "Gene: ITLN1 (chromosome 1q22)",
        "Protein: 313 amino acids; circulates as a homotrimer",
        "Primary source: visceral adipose stromal vascular fraction (not mature adipocytes)",
        "Also expressed in: small intestinal Paneth cells, colon, thymus",
        "Two isoforms described: omentin-1 (predominant circulating form) and omentin-2",
      ],
    },
    {
      type: "subheading",
      text: "Insulin-Sensitizing Mechanisms",
    },
    {
      type: "paragraph",
      text: "Omentin enhances insulin-stimulated glucose uptake in human adipocytes via Akt phosphorylation, apparently without direct insulin receptor binding, suggesting a downstream sensitization mechanism. In vascular smooth muscle cells, omentin has been shown to inhibit TNF-α-induced NF-κB activation and reduce inflammatory gene expression. In endothelial cells, omentin promotes nitric oxide production via eNOS phosphorylation, suggesting vasoprotective properties.",
    },
    {
      type: "subheading",
      text: "Clinical Research Correlations",
    },
    {
      type: "paragraph",
      text: "Plasma omentin-1 levels are consistently lower in obese individuals, type 2 diabetics, and those with metabolic syndrome compared to lean healthy controls. Weight loss interventions (including bariatric surgery) increase circulating omentin-1 in most human studies. Omentin-1 has also been positively correlated with coronary artery calcification scores in reverse — lower omentin-1 associating with more calcification — suggesting a potential cardioprotective role. Researchers studying cardiometabolic phenotypes commonly measure omentin-1 via commercial ELISA as a secondary biomarker endpoint.",
    },
    {
      type: "heading",
      text: "Vaspin (Visceral Adipose Tissue-Derived Serpin)",
    },
    {
      type: "subheading",
      text: "Biology and Discovery",
    },
    {
      type: "paragraph",
      text: "Vaspin was identified in 2005 from visceral adipose tissue of Otsuka Long-Evans Tokushima Fatty (OLETF) rats — a model of type 2 diabetes and obesity. Its name derives from 'visceral adipose tissue-derived serine protease inhibitor' (serpin). Vaspin belongs to the serpin superfamily and is encoded by the SERPINA12 gene. Importantly, vaspin has an identified protease target: kallikrein-7 (KLK7), a serine protease involved in skin barrier function and epidermal desquamation, which expands its research interest beyond pure metabolic contexts.",
    },
    {
      type: "list",
      items: [
        "Gene: SERPINA12 (chromosome 14q32.13)",
        "Protein: ~47 kDa; classical serpin fold",
        "Identified protease target: kallikrein-7 (KLK7)",
        "Expressed in: visceral white adipose tissue, liver, skin",
        "Peak expression occurs at maximal insulin resistance in animal models",
      ],
    },
    {
      type: "subheading",
      text: "Metabolic Research",
    },
    {
      type: "paragraph",
      text: "Vaspin administration in obese diabetic OLETF rats improved glucose tolerance, enhanced insulin sensitivity, and normalized expression of several metabolic genes including TNF-α and resistin. These early findings established vaspin as a potential compensatory adipokine — upregulated in response to insulin resistance as a counter-regulatory mechanism. In vitro studies have shown vaspin can inhibit lipid-induced apoptosis in endothelial cells and suppress NF-κB-mediated inflammatory signaling.",
    },
    {
      type: "subheading",
      text: "Human Research Context",
    },
    {
      type: "paragraph",
      text: "Human plasma vaspin levels show a complex, non-linear relationship with metabolic parameters — elevated in obese/diabetic individuals compared to lean controls, but declining with extreme obesity and poorly controlled diabetes, consistent with the compensatory upregulation model. Vaspin levels are also modulated by insulin treatment, exercise, and bariatric surgery in clinical studies. In polycystic ovary syndrome (PCOS) research, vaspin has been studied as a potential biomarker of ovarian metabolic dysfunction.",
    },
    {
      type: "heading",
      text: "Comparative Summary",
    },
    {
      type: "table",
      headers: ["Adipokine", "Primary Source", "Metabolic Effect", "Inflammatory Role", "Key Research Use"],
      rows: [
        ["Visfatin/eNAMPT", "Visceral adipocytes, immune cells", "Complex/context-dependent", "Pro-inflammatory", "NAD+ metabolism, cancer, CVD biomarker"],
        ["Resistin", "Macrophages (humans)", "Insulin resistance (rodents); indirect (humans)", "Pro-inflammatory (humans)", "CVD, IBD, autoimmune endpoints"],
        ["Omentin-1", "Visceral stromal vascular cells", "Insulin-sensitizing", "Anti-inflammatory", "Cardiometabolic phenotyping, obesity biomarker"],
        ["Vaspin", "Visceral adipocytes", "Insulin-sensitizing (compensatory)", "Anti-inflammatory", "PCOS, T2D, skin barrier research"],
      ],
    },
    {
      type: "heading",
      text: "Research Design Considerations",
    },
    {
      type: "paragraph",
      text: "Investigators incorporating these adipokines as biomarkers or experimental endpoints should account for the following:",
    },
    {
      type: "list",
      items: [
        "Diurnal variation: plasma levels of several adipokines (including visfatin) show circadian patterns — standardize blood collection time",
        "Fasting state: adipokine levels are influenced by postprandial state; protocol should specify fasting duration",
        "Body fat distribution: visceral vs. subcutaneous fat depots express these proteins differentially; body composition assessment is informative",
        "Species: resistin biology differs fundamentally between rodents and humans — interpret rodent data with caution for translational studies",
        "ELISA specificity: cross-reactivity between isoforms (e.g., omentin-1 vs. omentin-2) varies by commercial assay; verify antibody specificity",
        "Exercise acutely modulates omentin, vaspin, and visfatin — control for physical activity in study protocols",
      ],
    },
    {
      type: "heading",
      text: "Peptide Sourcing for Research",
    },
    {
      type: "paragraph",
      text: "Recombinant or synthetic forms of these adipokines are available for in vitro research applications. For functional studies (e.g., insulin-sensitization assays, endothelial protection protocols), recombinant protein quality is critical. Researchers should verify endotoxin levels (<1 EU/μg), confirm biological activity using established functional assays (e.g., Akt phosphorylation for omentin, NF-κB reporter for resistin), and use appropriate positive controls. For biomarker studies, validated sandwich ELISA kits with established reference ranges in human plasma are the standard approach.",
    },
    {
      type: "callout",
      text: "Nexphoria provides research-grade peptides with documented purity by HPLC and identity by mass spectrometry for investigational use. All compounds are provided for research purposes only.",
    },
    {
      type: "heading",
      text: "Key References",
    },
    {
      type: "list",
      items: [
        "Fukuhara A et al. (2005). Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. — Original visfatin characterization.",
        "Steppan CM et al. (2001). The hormone resistin links obesity to diabetes. Nature. — Original resistin identification.",
        "Yang RZ et al. (2006). Identification of omentin as a novel depot-specific adipokine in human adipose tissue. Biochem Biophys Res Commun.",
        "Hida K et al. (2005). Visceral adipose tissue-derived serine protease inhibitor: A unique insulin-sensitizing adipocytokine. PNAS. — Original vaspin identification.",
        "Rabe K et al. (2008). Adipokines and insulin resistance. Mol Med. — Comprehensive review of adipokine biology.",
        "Blüher M (2013). Adipokines: removing road blocks to obesity and diabetes therapy. Mol Metab. — Translational context review.",
      ],
    },
    {
      type: "disclaimer",
      text: "This article is intended for research and educational purposes only. The adipokines described are not approved for therapeutic use. All information reflects peer-reviewed preclinical and observational research and does not constitute medical advice.",
    },
  ],
};
